Alan Urban
Equibles does not estimate personal net worth.
Get an email with a short summary when GT Biopharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get GTBP alertsAbout Alan Urban
Alan Urban is recorded as CFO at GT Biopharma, Inc. (GTBP). The newest filing on record that lists Alan Urban as CFO at GT Biopharma, Inc. (GTBP) is dated July 2, 2026. Earlier roles on record: CFO at Research Solutions, Inc. (RSSS) until October 4, 2021. GT Biopharma, Inc. reported in an 8-K filed May 4, 2023 that Alan Urban resigned as member of the Board of Directors, effective May 1, 2023. The proxy statement of GT Biopharma, Inc. reports total compensation of $739,310 for Alan Urban in fiscal 2025, including a base salary of $393,750. Disclosed compensation is on record for 2 fiscal years. Alan Urban has spoken on 4 earnings calls across 1 company, most recently for Research Solutions, Inc. on June 30, 2021. GT Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Alan Urban spoke on are classified in the Technology sector. Other leadership on record at GT Biopharma, Inc. includes Anthony Cataldo (CEO), Dr. Gregory Berk (CEO), Michael Breen (CEO and Board Member) and 7 others.
“On May 1, 2023 Alan Urban resigned as a member of the Registrant's Board of Directors (the "Board").”
Alan Urban on recent calls
“For the fourth quarter fiscal 2021, total revenue was $8.2 million, a 4.2% increase from the fourth quarter of fiscal 2020.”
“Second quarter total revenue was $7.4 million compared to $7.5 million in the second quarter of fiscal 2020. Our Platform subscription revenue increased 29% to $1.2 million, primarily driven by a net increase of Platform deployments from last year, including 29 new deployments in the second quarter.”
“For the fourth quarter of fiscal year 2020, total revenue was $7.9 million, a 5.5% increase from the fourth quarter of fiscal 2019.”
“Jumping right into our fiscal Q2 results, our platform subscription revenue increased 42% to $950,000, driven by a 27% year-over-year increase in total platform deployments from 267 to 338, which translates into 18 net incremental deployments in Q2.”
Affiliation history
-
Current
Start not stated–present
Last confirmed July 2, 2026
-
Start not stated–2021-10-04
Company network
Software - Application · Technology
CFO
Leadership on record at GT Biopharma, Inc.
- Anthony Cataldo CEO
- Dr. Gregory Berk CEO
- Michael Breen CEO, Board Member
- Bruce Wendel Chairman
- Alan L. Urban CFO, Board Member
- Dr. Gavin Choy CFO
- Michael Handelman CFO
- Andrew Ritter Board Member
- Charles J. Casamento Board Member
- David C. Mun-Gavin Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | GT Biopharma, Inc. (GTBP) | Chief Financial Officer | $393,750 | $739,310 |
| 2024 | GT Biopharma, Inc. (GTBP) | Chief Financial Officer | $218,750 | $377,782 |